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Abstract 
CCN2/connective tissue growth factor (CTGF) is a unique molecule that promotes both 
chondrocytic differentiation and proliferation through its matricellular interaction with a 
number of extracellular biomolecules.  This apparently contradictory functional 
property of CCN2 suggests its certain role in basic cellular activities such as energy 
metabolism, which is required for both proliferation and differentiation.  Comparative 
metabolomic analysis of costal chondrocytes isolated from wild-type and Ccn2-null 
mice revealed overall impaired metabolism in the latter.  Among the numerous 
metabolites analyzed, stable reduction in the intracellular level of ATP, GTP, CTP or 
UTP was observed, indicating a profound role of CCN2 in energy metabolism.  
Particularly, the cellular level of ATP was decreased by more than 50 % in the Ccn2-null 
chondrocytes.  The addition of recombinant CCN2 (rCCN2) to cultured Ccn2-null 
chondrocytes partly redeemed the cellular ATP level attenuated by Ccn2 deletion.  
Next, in order to investigate the mechanistic background that mediates the reduction in 
ATP level in these Ccn2-null chondrocytes, we performed transcriptome analysis.  As 
a result, several metabolism-associated genes were found to have been up-regulated or 
down-regulated in the mutant mice.  Up-regulation of a number of ribosomal protein 
genes was observed upon Ccn2 deletion, whereas a few genes required for aerobic and 
anaerobic ATP production were down-regulated in the Ccn2-null chondrocytes.  
Among such genes, reduction in the expression of the enolase 1 gene was of particular 
note.  These findings uncover a novel functional role of CCN2 as a metabolic 
supporter in the growth-plate chondrocytes, which is required for skeletogenesis in 
mammals.   
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Introduction 
Endochondral ossification is a critical process that determines the skeletal size of 
vertebrates (Kubota and Takigawa, 2007, 2011; Takigawa, 2013).  This sophisticated 
process is initiated during the development of long bones, which begin as cartilage 
anlagen, and remains active until the cessation of body growth.  Even after the 
completion of skeletal growth, endochondral ossification recurs upon bone injury and 
fracture as a central procedure to regenerate bone defects; and it thus is an indispensable 
biological process throughout life.   
The central player of endochondral ossification is the growth-plate chondrocyte, the cell 
responsible for the growth of long bones and one that follows a characteristic pathway 
of differentiation.  Chondrocytes differentiate from condensed mesenchyme and begin 
to produce cartilaginous extracellular matrix (ECM) components, such as type II 
collagen and aggrecan, to form and support the integrity of the cartilage anlagen.  
These cells initially remain in a quiescent stage and are designated as resting 
chondrocytes.  Subsequently, these resting chondrocytes begin to proliferate, causing 
the growth of the anlagen while forming a columnar alignment of themselves.  After 
the proliferative stage, these cells undergo a maturation process.  Next, chondrocytes 
near the bone-cartilage junction in the growth plate differentiate into hypertrophic 
chondrocytes, which cells induce matrix vesicle-mediated calcification, producing type 
X collagen and matrix metalloproteinase 13 (MMP-13).  This calcifying hypertrophic 
layer of the growing cartilage is invaded by blood vessels and finally replaced by bone 
tissue (Kubota and Takigawa, 2007, 2011; Takigawa, 2013).        
In general, cell proliferation and differentiation are thought to be biologically 
incompatible events.  Consistent with this notion, a significant number of extracellular 
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signaling factors that promote either proliferation or differentiation have been reported. 
For example, fibroblast growth factor 2 (FGF2) (Weksler et al., 1999) promotes the 
proliferation of growth-plate chondrocytes while inhibiting their differentiation.  
Contrarily, parathyroid hormone (PTH) evidently enhance chondrocytic differentiation, 
whereas they exert no significant effect on cell proliferation (Takigawa et al., 1981) .  
However surprisingly, CCN2 was re-discovered as a factor that could promote both cell 
proliferation and differentiation and even hypertrophy of chondrocytes throughout the 
process of endochondral ossification. (Takigawa et al., 2003; Perbal and Takigawa, 
2005)   
CCN2, also known as connective tissue growth factor (CTGF), is a member of the CCN 
family of secreted multi-functional proteins (Brigstock et al., 2003; Perbal, 2004; Perbal 
and Takigawa, 2005; Leask and Abraham, 2006; Jun and Lau, 2011).  Previous studies 
showed that the addition of exogenous CCN2 to cultured chondrocytes promoted the 
proliferation and enhanced their synthesis of proteoglycans concomitant with elevated 
expression of chondrocyte-associated genes.  These data in vitro indicate that CCN2 
indeed promotes the proliferation and differentiation of chondrocytes (Nakanishi et al., 
1997, 2000; Nishida et al., 2000, 2002).  Moreover, in other previous studies in vivo, 
proliferative defect was indicated in chondrocytes in neonatal growth plates of 
Ccn2-null mice (Ivkovic et al., 2003; Kawaki et al., 2008).  In the same studies, it was 
also shown that Ccn2-deficient growth-plate cartilage exhibits defects in extracellular 
matrix formation.  These in vivo data firmly support the in vitro finding that CCN2 is a 
promoter of cell proliferation and differentiation during endochondral ossification.  
The mechanism by which CCN2 enhances these apparently incompatible events has 
remained unclear.  However, considering that both of these activities require energy 
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consumption, it is evident that both cell proliferation and differentiation are supported 
by and under the control of the metabolic system providing energy.  Thus, in this 
present study we aimed at examining the critical role of CCN2 in the energy metabolism 
of growth-plate chondrocytes.   
 
 
Materials and Methods 
Histochemical analysis 
The CCN2-KO mice used in this study were previously described (Ivkovic et al., 
2003).  Hind limbs removed at embryonic day (E) 18.5 or E19.5 were fixed with 4% 
paraformaldehyde (PFA) in 0.1 M phosphate buffer (pH 7.4) for 24 h.  The samples 
were then decalcified with 10% EDTA for 3–7 days, depending on their age prior to 
embedment in paraffin.  Preparation of thin sections and Alcian blue staining was 
performed as described previously (Kawaki et al., 2008).  Paraffin sections after 
staining were examined under a Microphoto FXA light microscope equipped with a 
DXM1200 digital camera (Nikon, Kawasaki, Japan).  All animal experiments in this 
study were conducted according to the Guidelines for Animal Research of Okayama 
University and were approved by the animal committee. 
 
Cell culture 
Costal chondrocytes were isolated from rib cartilage of Ccn2-null mice and wild- 
type littermates at E18.5 or E19.5, following an established protocol as previously 
described (Kawaki et al., 2008; Hattori et al., 2010).  Briefly, after careful elimination 
of soft tissues by digestion with 0.05% trypsin for 5 min at 37°C, the cartilage was 
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digested with 3 mg/ml collagenase A (Roche, Basel, Switzerland) for 1.5h at 37°C to 
liberate the chondrocytes.  These cells were then inoculated into 6-well multiplates 
containing Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% 
fetal bovine serum (FBS) and incubated at 37°C under 5% CO2 in air.  The isolated 
chondrocytes were utilized for experiments within 2 passages in culture.  Occasionally, 
the cells were treated with recombinant human CCN2 (Nakanishi et al., 2000) for the 
desired time period.  
   
Metabolome analysis  
Extraction of total metabolites from murine chondrocytes was performed by the 
method recommended by Human Metabolome Technologies (Tsuruoka, Japan).  The 
cells isolated from rib cage cartilage were inoculated into a 6-well multi-plate at a 
density of 3.6 × 10
5
 cells/well and were cultured.  At confluence, the cells were 
washed with 5% mannitol solution (Wako, Osaka, Japan) twice and then were scraped 
and transferred to a centrifuge tube after the addition of methanol containing 10 µM 
Internal Standard Solution (Human Metabolome Technologies).  They were 
immediately frozen and stored at -80°C until metabolite extraction could be performed.  
Prior to the analysis, these samples were mixed with chloroform and ultra pure water 
and centrifuged at 5,000×g for 5 min at 4°C.  For removal of proteins, the sample was 
centrifugally passed through a filter (5 kDa, MILLIPORE, Billerica, MA).  The 
filtrates were centrifuged and dissolved in 25 µl of ultra pure water.  Then cationic and 
anionic metabolite analysis with a capillary electrophoresis time-of-flight mass 
spectrometer (CE-TOFMS) was performed (Agilent CE-TOFMS system, Agilent 
Technologies Japan, Ltd., Tokyo, Japan).  Cationic metabolites were analyzed by using 
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a fused silica capillary (i.d. 50 µm×80 cm), with Cation Buffer Solution (Human 
Metabolome Technologies) as the electrolyte at an injection pressure of 50 mbar for 10 
sec, where the applied voltage was 27 kV.  Electrospray ionization-mass spectrometry 
(ESI-MS) was performed in the positive-ion mode.  The applied capillary voltage was 
set at 4,000V and the scan range of the spectrometer was from 50 to 1,000 
mass-to-charge ratio (m/z).  Anionic metabolites were analyzed with Anion Buffer 
Solution (Human Metabolome Technologies) as the electrolyte at an injection pressure 
at 50 mbar for 25 sec, with an applied voltage of 30 kV.  ESI-MS was performed in the 
negative-ion mode.  The applied capillary voltage was set at 3,500V and the scan range 
of the spectrometer was from 50 to 1,000 m/z.  The peaks detected by CE-TOFMS 
were processed by using software (MasterHands ver.2.9.0.9, Keio Univ., Tokyo, Japan).  
In this way, m/z value, migration time, and peak area level were obtained.  The peak 
area level was converted into a relative area level per cell by the following expression:  
Relative area level – objective peak area / (the area of an internal material × cell count) 
As target materials, 108 substances including amino acids, organic acids, sugar 
phosphoric acids, and the nucleic acids were analyzed.  The concentration of each 
material was calculated in reference to the concentration of the internal standard 
material (200 µM).  
 
RNA extraction and real-time reverse-transcription polymerase chain reaction 
(RT-PCR) analysis 
Total RNA was extracted and purified by using an RNeasy Mini Kit according to 
the manufacturer’s instructions (Qiagen, Hilden, Germany) and was then 
reverse-transcribed to cDNA by use of avian myeloblastosis virus reverse transcriptase 
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with an oligo d(T) as a primer (TaKaRa RNA PCR
TM
 Kit Ver.3.0, Takara Shuzo, Tokyo, 
Japan).  Quantitative real-time PCR was carried out by using TOYOBO SYBR Green 
PCR Master Mix (TOYOBO, Osaka, Japan) with a StepOnePlus
TM
 Real-Time PCR 
Systems (Applied Biosystems, CA).  Primers used for the amplification of each cDNA 
were as follow: 5'- GAC AGA GTG GGA GGC GCT TA -3' (sense) and 5'- CTG AGA 
ATA GAC ATG GCG AAT TTC -3' (antisense) for murine Eno1; 5'- GCG AAT TCC 
TGC CAG TAG CAT ATG CTT G -3' (sense) and 5'- GGA AGC TTA GAG GAG CGA 
GCG ACC AAA GG -3' (antisense) for murine and human r18s; 5'- GCA GGC TAG 
AGA AGC AGA GC -3' (sense) and 5'- ATG TCT TCA TGC TGG TGC AG -3' 
(antisense) for human CCN2.  Formation of proper amplicons was confirmed by 
melting curve analysis.  Data were standardized against the level of 18s rRNA.   
 
ATP quantification by bioluminescence assay 
 The intracellular ATP level was measured by use of an ATP bioluminescence 
assay kit (Roche), according to manufacturer’s recommendations.  Briefly, Ccn2-null 
and WT chondrocytes were initially inoculated at a density of 3.6-3.7 × 10
5
 cells/well 
into 6-well multiplates.  After reaching confluence, the cells were seeded at a density 
of 2 × 10
5
 cells/well into 24-well multiplates and further cultured.  At confluence, the 
chondrocytes were collected and suspended in 100 µl of phosphate-buffered saline 
(PBS).  Next, 9 volumes of boiling hot 100 mM Tris-HCl containing 4 mM EDTA 
(pH7.75) was added to the cell suspension, and the cells were boiled for 2 min and 
thereafter centrifuged at 1,000 x g for 60 s.  Fifty microliters of sample/standard was 
transferred to each well in a 96-well plate.  Then, the luciferase reagent was added to 
the sample/standard, and the emitted light was measured with a luminometer 
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(Fluoroskan Ascent FL, Thermo Lab Systems, Franklin, MA).    
        
CCN2 Gene Silencing by an siRNA 
CCN2 siRNA (Silencer
® 
select Validated siRNA) and negative control siRNA 
(Silencer
® 
select Negative control siRNA) were purchased from Life Technologies 
(Carlsbad, CA).  Si RNA was delivered into the cells by electroporation using 
Amaxa
TM
 Human Chondrocyte Nucleofector
TM
 kit (Lonza) and Amaxa Nucleofector
®
 
Ⅱ (Amaxa Biosystems) according to the manufacturer’s instructions.  In brief, human 
chondrocytic cell line HCS-2/8 cells (1.0×106) were transfected with 100μM siRNAs 
in the solution for electroporation (Nucleofector solution and supplement: 100μl) using 
electroporation program U-024.  Then the cells in DMEM supplemented with 10% 
FBS were seeded at a density of 1.0×106 cells/ well into 6-well plate for RNA 
extraction and at a density of 2.0×105 cells/ well into 24-well for ATP bioluminescence 
assay and were incubated at 37°C under 5% CO2 in the air.  After 24 hours, the cells 
were collected for subsequent analyses.  
 
Microarray analysis 
 Comparative transcriptome analysis was performed by using a mouse Panorama 
Micro Array (Sigma, St Louis, MO) according to the manufacturer's instruction.  Total 
RNA was extracted from 8 individual mouse embryos from 4 different litters at an 
embryonic day described elsewhere and was mixed before being subjected to labeling.  
Signals were captured and quantified by use of a GenePix 4000B (Molecular Devices, 
Sunnyvale, CA).   
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Evaluation of mitochondrial membrane potential 
 A mitochondrion-specific thiol-reactive fluorescent probe (Mito tracker
®
 RED 
CM-H2XRos, Invitrogen, Carlsbad, CA) was employed for the evaluation of the 
mitochondrial membrane potential.   Ccn2-KO and wild-type chondrocytes were 
grown to subconfluence in 24-well multiplates and 4-well slide chambers, treated with 
200 nM Mito tracker at 37℃ for 30 min, washed with PBS, and fixed in 3.7% 
formaldehyde at 37℃  for 15 min.  Thereafter, PBS containing 1 µg/ml of 
4’,6-diamidino-2-phenylindole (DAPI) was added for nuclear staining.  Quantitative 
and qualitative evaluations of mitochondrial activity were conducted by using a 
high-content analyzing system (Cellomics
TM
 ArrayScan
®
 VTL System, ThermoFisher 
SCIENTIFIC, Waltham, MA) and an automated microscope (BZ9000, Keyence, Osaka, 
Japan).   
 
Statistical Analysis 
The results obtained from quantitative experiments were reported as the mean 
values +/- standard deviation (SD).  Statistical comparisons between the groups were 
performed by using Student’s t-test.  Unless otherwise specified, all experiments were 
repeated at least twice, and comparable results were obtained.   
 
 
Results 
Depressed biological activities observed in the cartilage of Ccn2-null mice 
As found previously (Ivkovic et al., 2003; Kawaki et al., 2008), growth 
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retardation and delayed chondrocyte differentiation were observed in the Ccn2-null 
mice (Fig. 1A), which findings are in line with our hypothesis that CCN2 may support 
basic metabolism during cartilage development.  First of all, in order to confirm these 
findings, we comparatively reevaluated the production of cartilaginous ECM in vivo, 
which is the most proper and critical characteristic of chondrocytes.  As clearly 
observed in Fig. 1B, compared with that in the wild type tissue, the content of Alcian 
blue-stained sulfated proteoglycans was markedly reduced in the developing cartilage 
from the Ccn2-null mice.  This result is entirely consistent with previous reports 
indicating impaired ECM synthesis in the cartilaginous tissues in Ccn2-null mice 
(Ivkovic et al., 2003).  Synthesizing proteoglylcans is a series of anabolic events that 
requires energy support.  Considering that cell proliferation is also impaired in those 
cells, these findings collectively suggest depressed energy supply in Ccn2-null 
chondrocytes.   
 
Metabolic profiles of Ccn2-null chondrocytes that represent a deficiency in basic 
energy supply system.  
In the living body, a large part of energy is captured through the catabolic pathway, 
in which acetyl-coenzyme A (CoA) is central.  For the comprehensive evaluation of the 
metabolic outcome of Ccn2 deletion, metabolome analysis was employed.  Absolute 
quantification of 108 metabolites by CE-TOF MS analysis revealed that the intracellular 
levels of a number of metabolites were affected by Ccn2 deletion.  Among the 
catabolic pathways, glycolysis is known as the most fundamental one for energy 
production, which process is conserved among most organisms.  Also, this pathway is 
regarded as a major catabolic pathway for chondrocytes, since cartilage is an avascular 
12 
 
tissue and thus under hypoxic conditions.  Comparative quantification of glycolytic 
metabolites upstream (Fig. 2A) and downstream (Fig. 2B) of glyceraldehyde 
3-phosphate indicated that the intracellular levels of all of the metabolites measured in 
the Ccn2-null chondrocytes were reduced compared with those in the wild-type ones.  
Particularly, the low level of acetyl-CoA should be noted.  The observed overall 
decrease in the levels of these glycolytic metabolites suggests a fundamental deficiency 
in the metabolic pathway for biological energy production in the Ccn2-null 
chondrocytes. 
 
Intractable decrease in the intracellular ATP and other high-energy mononucleotides 
in Ccn2-null chondrocytes 
We repeated the whole quantitative metabolome analysis twice and found 
remarkable variances in a number of metabolites between 2 experiments.  In Fig. 3, the 
results of 2 independent sets of experiments with independent animals are 
comparatively plotted.  Obviously, a major part of metabolites were reproducibly 
decreased in the Ccn2-null choncrocytes (dots in the blue square); whereas no 
metabolites with a reproducible increase in these chondrocytes were noted (no dots in 
the red square).  Several metabolites showed quite large variance between the 2 
experiments.   For example, the hypoxanthine level in Ccn2-null chondrocytes was 
less than that in the wild type in the first evaluation, whereas in the second evaluation, it 
was more than twice higher in the Ccn2-null cells.  However, out of 100 metabolites, 
only 6 of them on the diagonal in Fig. 3 reproducibly yielded a stable reduction in the 
Ccn2-null chondrocytes.  Interestingly, ATP was included among these 6 metabolites 
(the red dot in Fig. 3) and showed the second-largest reduction in Ccn2-null cells among 
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these metabolites.  It should be also noted that the intracellular levels of other 
high-energy mononucleotides, i.e., GTP, CTP, and UTP, were also always decreased by 
Ccn2 deletion (Fig. 4A and B).  The fact that the relative ratio among the 4 
mononucleotides was comparable between Ccn2-null and wild-type chondrocytes (Fig. 
4A) indicates that the mutual interchange system among these nucleotides was not 
affected by the Ccn2 deletion.  Considering the stability and strength of the effect of 
the Ccn2 deletion on it, together with its having the highest intracellular level among the 
4 nucleotides, ATP would supposedly be a critical metabolic target of CCN2 in 
chondrocytes.   
 
Recovery of the intracellular ATP level in Ccn2-null chondrocytes by the addition of 
exogenous CCN2 in vitro 
The results of metabolome analysis via CE-mass spectrometry clearly indicated 
the requirement of CCN2 for the maintenance of high cellular ATP levels.  This finding 
was further confirmed by a different experimental strategy with a bioluminescence 
quantification of ATP activity.  As exactly indicated by the metabolome analysis, the 
results of the ATP bioluminescence assay also showed that the ATP level in Ccn2-null 
chondrocytes was decreased by more than 50% in comparison with that in the wild-type 
ones  (Fig. 5A).  Utilizing this experimental system, we tested if exogenous CCN2 
could rescue the defect in ATP level caused by the Ccn2 deletion.   We added human 
recombinant CCN2 to cultures of Ccn2-null and wild-type chondrocytes and evaluated 
its effect.   This recombinant CCN2 was also used for our very recent study describing 
the cartilage regenerative effects of CCN2 derivatives and actually showed sufficient 
biological activities in vitro and in vivo (Abd El Kader et al., 2013).  As expected, the 
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intracellular ATP level in the Ccn2-null chondrocytes was recovered by the treatment 
with exogenous CCN2 for 48 h (Fig. 5B), whereas it was not significantly by the 
treatment for 24 h.  Of note, the addition of the same amount of CCN2 to the wild-type 
cultures appeared to increase the ATP level modestly in them as well.  Considering that 
CCN2 enhances cell proliferation and ECM production, both energy-dependent 
processes, it is reasonable that CCN2 was capable of enhancing ATP synthesis in the 
chondrocytes.   
 
Reduction of ATP level in human chondrocytic cells by transient silencing of CCN2  
Since permanent Ccn2 deletion affects the differentiation of growth plate 
chondrocytes, cellular compositions along with the differentiation may differ between 
Ccn2-null and wild type growth plates, which may affect metabolic profiles.  In order 
to rule out this possibility, we utilized a human chondrocytic cell line, HCS-2/8, which 
is widely known to stably retain mature chondrocytic phenotype.  By using a synthetic 
siRNA, CCN2 expression was transiently silenced in HCS-2/8 cells, and cellular ATP 
level was evaluated.  As a result, cellular ATP level was significantly reduced in 
CCN2-silenced HCS-2/8 cells (Fig. 6).  Therefore, ATP reduction in CCN2-depleted 
chondrocytes is not due to the altered cellular composition, but is caused by individual 
cellular events.     
 
Effect of Ccn2 depletion on the expression of various components of the metabolic 
machinery  
Next, in order to identify genes that mediated the observed phenotypic changes 
upon Ccn2 deletion, we performed transcriptome analysis.  RNA was extracted and 
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mixed from 8 individual Ccn2-null or wild-type mice from 3 different litters in order to 
minimize possible individual variation.   Microarray analysis of these RNA mixtures 
showed that the long-term lack of CCN2 increased the expression level of several 
ribosomal protein genes, i.e., Rpl38, Rpl2, Rpl26 and Rpl35 (Fig. 7A).  Ccn3, which is 
another member of the CCN family, was also up-regulated in the Ccn2-null 
chondrocytes, as previously reported (Kawaki et al., 2008).  Contrarily, in addition to 
the genes encoding cartilaginous ECM components, such as type 9 procollagen and 
aggrecan, a few genes closely related to energy metabolism were repressed by Ccn2 
deletion (Fig. 7B).  One such gene was Atp5l, encoding the ATP synthase subunit  in 
the ATP synthase complex, a critical mitochondrial molecular motor that supplies a 
major part of cellular ATP through the respiratory chain.  In addition, the enolase 1 
gene, encoding an enzyme built into the glycolytic pathway, was also found by 
microarray analysis to have been down-regulated.    
 
Effect of Ccn2 depletion on mitochondrial activity and Eno1 expression in 
chondrocytes 
Subsequently, since we found a possible defect in the mitochondrial energy 
production system through microarray analysis, we next evaluated the biological 
activity of mitochondria in Ccn2-null chondrocytes.   Utilizing Mitotracker, which 
contained a mildly thiol-reactive chloromethyl moiety, we fluorescently labeled only the 
active mitochondria, in which oxidative phosphorylation occurred.  As a result, active 
mitochondria were efficiently detected in both wild-type and Ccn2-null chondrocytes.  
Although we observed stronger signals in chondrocytes from a few of the wild-type 
mouse embryos examined (Fig. 8A), quantitative analysis of chondrocytes from several 
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more animals revealed no significant difference in mitochondrial activity between 
wild-type and Ccn2-null chondrocytes (data not shown).  These results suggest a 
limited involvement of the mitochondria in the observed ATP deficiency in Ccn2-null 
chondrocytes and a relatively minor role of the respiratory chain as a source of ATP in 
chondrocytes.   
 Attenuated glycolysis in Ccn2-null chondrocytes was also suggested by the data 
shown in Fig. 2, in which case the involvement of the Eno1 gene was strongly suspected 
based on the data in Fig. 7.  In order to confirm the repression of the Eno1 gene in 
Ccn2-null chondrocytes, we performed quantitative real-time RT-PCR analysis and 
obtained the expected results (Fig. 8B).  Therefore, these data strongly suggest that 
CCN2 regulated ATP production mainly through the anaerobic pathway, specifically 
targeting the enolase gene.   
 
 
Discussion 
 
Our present study clearly indicated that the intracellular ATP level was maintained at a 
higher level in chondrocytes in the presence of CCN2 than in its absence.  However, 
albeit at a reduced rate, even Ccn2-null chondrocytes were still capable of proliferating 
and differentiating even with a drastically reduced intracellular ATP level.  Here, we 
should note that the quantity of ATP we measured does not represent the total quantity 
that the cell actually produces and consumes.  In the cells, ATP is continuously 
produced and readily used for any anabolic cellular activity.  What we could measure 
was the ATP present in the cells.  Interestingly, when we lowered the concentration of 
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FBS in the medium of Ccn2-null chondrocytes to an extremely low one, resulting in 
cellular dormancy, the quantity of intracellular ATP rose strikingly (data not shown).  
Thus, even in the absence of CCN2, the chondrocytes were capable of producing the 
minimal energy to support their basic life functions.   
Next, the mechanism by which CCN2 was supporting ATP synthesis was investigated.  
The results of DNA microarray analysis showed that the lack of CCN2 during 
development resulted in increased expression of ribosomal protein genes and decreased 
that of several ECM and metabolism-associated genes.  Of note, these genes included 
the ATP synthase subunit  gene, the product of which constructs the central shaft of the 
rotator of the mitochondrial molecular motor (von Ballmoos et al., 2009).  The 
increase in ribosomal protein gene expression could be the outcome of the 
compensatory survival reaction under energy deficient conditions.  Suspecting 
depressed mitochondrial activity in Ccn2-null chondrocytes, we next evaluated the 
mitochondrial membrane potential.  However unexpectedly, no drastic difference in 
the membrane potential was observed between Ccn2-null and wild-type chondrocytes.  
ATP production through oxidative phosphorylation in mitochondria is the major 
pathway for cells under normoxic conditions, whereas chondrocytes survive in an 
avascular microenvironment.  Under such an environment, the significance of 
oxidative phosphorylation for the supply of energy would be expected to be relatively 
minor, with the anaerobic glycolytic pathway playing the major role in ATP production.  
In fact in Fig. 2, we showed that the levels of glycolytic metabolites in Ccn2-null 
chondrocytes were overall lower than those in the wild-type ones.  Among these 
metabolites was phosphoenolpyruvate, formed from 2-phosphoglycerate by catalysis by 
enolase (Wold, 1971).  Enolase 1, commonly known as -enolase, is the major 
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isozyme of enolases.  Importantly, we found that its expression was significantly 
decreased in Ccn2-null chondrocytes, as determined by quantitative RNA analysis as 
well as by DNA microarray analysis.  We already reported that CCN2 activated 
extracellular signal-regulated kinase 1/2 in chondrocytes in our previous study 
(Yosimichi et al., 2006).  Importantly, another previous study showed that, through this 
enolase gene, extracellular signal-regulated kinase 1/2 (ERK1/2) regulates intracellular 
ATP levels in cardiomyocytes during ischemic hypoxia and reoxygenation (Mizukami et 
al., 2004).  Therefore, CCN2 possibly regulates glycolysis via Eno1 expression 
through ERK1/2 signaling pathway in chondrocytes, which is, at least in part, 
responsible for the observed effects of CCN2 on cellular ATP level.  However, the cell 
surface receptor that initiates this signaling is not defined yet.  In addition, since CCN2 
interacts a number of other growth factors, indirect effects mediated by such cofactors 
may not be overlooked.  Further investigation to clarify the mechanism of the CCN 
action in detail is currently ongoing.      
ATP is the most important molecule that mediates biological energy transfer for a 
variety of processes in living organisms.  Therefore, a critical basal level of cellular 
ATP must be present at all times.   In contrast, the CCN2 gene is known to be 
expressed at particular stages during the development of relevant organs (Kubota and 
Takigawa, 2007).  Moreover, Ccn2 expression is highly restricted to limited tissues in 
normal adults.  These findings again indicate that CCN2 is not indispensable for basic 
energy metabolism, but is occasionally utilized when an enhanced energy supply is 
requested.  The prominent induction of CCN2 observed upon wound healing is also 
consistent with this notion.  In the growth plate, CCN2 is produced in large quantities 
only by chondrocytes in the pre-hypertrophic layer (Kubota and Takigawa, 2007, 2011).  
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After being produced, CCN2 is transported and infiltrates in both directions in the 
growth plate, forming density gradients (Kawata et al., 2012).  On the resting side of 
the growth plate (upper portion in Fig. 8C), chondrocytes located near the CCN2 
producer receive strong CCN2 support that promotes their proliferation, whereas those 
farther away in the resting layer may not.  On the hypertrophic side, ATP production 
enhanced by a vast number of CCN2 molecule is utilized for early hypertrophic 
differentiation with vigorous ECM production.  CCN2 released in the bone marrow 
may also promote osteoblasts to proliferate and differentiate (Nishida et al., 2000; 
Safadi et al.,2003; Smerdel-Ramoya et al., 2008) and vascular endothelial cells to 
migrate (Shimo et al., 1998 and 1999; Babic et al., 1999) as well (Fig. 8C).  
Collectively, our results suggest that CCN2 plays an important role in endochondral 
ossification by enhancing ATP production where it is required.   
From a pathogenic point of view, it should be also noted that ATP depletion could be 
considered as a causative factor for the development of osteoarthritis (OA; Johnson et 
al., 2004).  According to a recent report, impaired ATP production induced by 
glycolysis inhibitors promotes chondrocyte hypertrophy-like changes leading to the 
onset and development of OA-like lesions (Nishida et al., 2013).  Furthermore, the 
application of CCN2 to rat OA models induces the regeneration of damaged articular 
cartilage (Nishida et al., 2004).  Considering these findings together with our present 
results, the anti-OA action of CCN2 may be ascribed to the functional property of 
CCN2, i.e., prevention of the depletion of ATP.  The utility of CCN2 in regenerative 
medicine for the treatment of cartilaginous tissues is again emphasized herein.    
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Figure Legends 
 
Fig. 1.  The phenotype in growth-plate cartilage of Ccn2-null mice, representing 
metabolic depression.  A. Overview of phenotypic changes caused by Ccn2 deletion.  
Findings observed in our previous study by Kawaki et al. are summarized.  Ccn2 
deletion caused a remarkable reduction in chondrocyte proliferation and extracellular 
matrix (ECM) synthesis and maturation in vivo and in vitro, which was accompanied by 
decreased expression of chondrocytic marker genes.  Note that Ccn3 expression was 
enhanced by Ccn2 deletion. B. Impaired proteoglycan synthesis in the growth plate 
revealed by Alcian blue staining.  Representative views at low power (upper panels) 
and high power (lower panels) magnifications are shown.  The reduced staining in the 
growth plate of this Ccn2-null mouse is consistent with the phenotype summarized in 
panel A.  Scale bars: 200 µm (upper panels); 100 µm (lower panels).   
 
Fig. 2.  Effects of Ccn2 deletion on the metabolites involved in glycolysis.  
Glycolytic metabolites upstream (A) and downstream (B) of glyceraldehyde 
3-phosphate in each type of chondrocyte were quantified.  The vertical axis of the 
graph represents metabolite content in 10
6
 chondrocytes (pmol/10
6
cells).  Open and 
solid columns represent the data from the wild-type and Ccn2-null chondrocytes, 
respectively.  The entire experiments were repeated twice, which always indicated 
lower levels of these metabolites in Ccn2-null mice (KO) than in the wild-type (WT) 
ones.  The mean values of 2 sets of the experiments are shown with error bars of 
standard deviations, except for fructose 6-phosphate that was not detectable in one of 
the experiments.   
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Fig. 3. Comparative analysis of the data obtained by 2 sets of metabolome analysis.  
Relative metabolite levels in Ccn2-null chondrocytes versus those in wild-type 
chondrocytes were computed for the metabolites that were successfully quantified in 
both sets of experiments.  The data from the first (ordinate) and second (abscissa) 
evaluations are plotted on the single graph.  Constant elevation of or reduction in 
levels of metabolites is indicated by the dots in the square areas shown in red or blue, 
respectively.  Note the absence of dots in the red square, whereas most of the dots are 
in the blue area, representing fundamental metabolic depression.  Dots on the dotted 
diagonal line represent the relative changes in metabolite levels that were exactly stable 
between 2 independent sets of experiments.  The red dot denotes the data for ATP; and 
the yellow ones, those for GTP, CTP and UTP.     
 
Fig. 4. Absolute quantification of high-energy mononucleotides in Ccn2-null and wild- 
type chondrocytes.  The mean values of the metabolite contents from independent 
metabolome analyses are shown with standard deviations.  A. Comparison among the 
mononucleotides in each type of chondrocyte.  Upper: Quantifications of ATP, CTP, 
GTP, and UTP in wild-type (WT) chondrocytes.  Lower: Quantifications of ATP, CTP, 
GTP and UTP in Ccn2-null chondrocytes.  The normal ratio among the mononcleotide 
contents observed in the wild type is retained in the Ccn2-null chondrocytes, with the 
highest level being that of ATP.  B. Comparison of nucleotide levels between the 
wild-type and Ccn2-null (KO) chondrocytes.  The levels of these high-energy 
mononuleotide in Ccn2-null chondrocytes (KO) were stably lower than those in the WT 
ones by approximately 50%.  The ordinate indicates the absolute content of each 
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mononucleotide (pmol/10
6
cells).  
 
Fig. 5. Effect of CCN2 on the intracellular ATP levels measured by a bioluminescence 
assay.  A. Comparison between Ccn2-null and wild-type chondrocytes.    
Chondrocytes were isolated from mice and cultured in 6-well multi-well plates as 
primary cultures.  After the cells had reached confluence, they were recollected and 
inoculated at a density of 2×105/plate into 24-well multi-well plates.  After 3 days, 
ATP quantification was performed as described in Materials and Methods.  By use of a 
BCA Protein Assay kit (Thermo Fisher Scientific), quantification of total proteins was 
also conducted to standardize the data.  The intracellular ATP levels are presented as 
relative amounts of ATP per total cellular protein.  Evaluation was performed in 
triplicate.  *p < 0.05, significantly different from wild type (WT) control.  B. Effect 
of exogenous CCN2 on the intracellular ATP levels.  The cells were prepared as 
described for panel A, incubated for 48 h in DMEM medium containing 50 ng/ml 
rCCN2/DMEM and 10% FBS, and then analyzed for their ATP level.  ATP levels are 
represented as relative values against those in KO cells without rCCN2 treatment.  
Data are means ±SD of relative values from each cell culture against the WT (-) 
control.  
 
Fig. 6. Effect of transient silencing of CCN2 on cellular ATP level in human 
chondrocytic HCS-2/8 cells.  A. Silencing of CCN2 by an siRNA.  HCS-2/8 cells 
were transfected with synthetic siRNA against CCN2 (siCCN2) or control (NC) RNA, 
and CCN2 mRNA was quantified 48 h later.  B. Quantification of cellular ATP under 
the same conditions as those for panel A.  Experiments were performed in 
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quadruplicate, and means ±SD are shown.  *p < 0.05 and **p < 0.01, significantly 
different from NC. 
 
Fig. 7. Effect of Ccn2 deletion on the expression of metabolism-associated genes in 
chondrocytes.  A. Genes up-regulated by Ccn2 deletion, as revealed by DNA 
microarray analysis.  Rpl38, Rpl2, Rpl26, and Rpl35 indicate the genes for ribosomal 
proteins L38, L2, L26, and L35, respectively.  Ccn3 is another CCN family member 
that was earlier reported to be up-regulated in CCN2-deficient mice.  B. Genes 
down-regulated by Ccn2 deletion, as revealed by DNA microarray analysis.  Eno1, 
Col9A1, Atp51, and Acan represent enolase 1, type 9 procollagen alpha 1 chain, ATP 
synthase subunit  and aggrecan genes, respectively.  Note that the expression of 2 of 
these energy metabolism-associated genes (underlined), as well as that of ECM 
component-encoding ones, was reduced by Ccn2 deletion.   
 
Fig. 8. Contribution of mitochondrial and glycolytic factors to the ATP deficiency in 
Ccn2-null chondrocytes.  A. Fluorescence staining of active mitochondria with 
membrane potential by Mitotracker.  Signals in wild-type (WT) chondrocytes appeared 
to be slightly stronger than those in Ccn2-null ones, but no statistically significant 
difference was observed between the two (data not shown).  B. Reduced gene 
expression of enolase 1, which is one of the major glycolytic enzymes, in Ccn2-null 
chondrocytes.  Data were obtained by real-time RT-PCR of the RNAs from the 
littermates, suggesting impaired glycolysis therein.  Evaluation was performed in 
triplicate.  **p < 0.01, significantly different from the WT control.  C. Role of CCN2 
as a metabolic supporter in the growth plate.  The growth plate is schematically 
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represented along with an illustration of a long bone.  RC, resting chondrocyte; PC, 
proliferating chondrocyte; PHC, pre-hypertrophic chondrocyte; HC, hypertrophic 
chondrocyte; VE, vascular endothelial cell, Ob, osteoblast.  Stars with "C" denote 
CCN2 molecules. In the process of endochondral ossification, CCN2 is mostly 
produced by pre-hypertrophic chondrocytes.  CCN2 stimulates the energy production 
to promote the proliferation of the proliferating chondrocytes on the upper side.  On 
the lower side, hypertrophic differentiation accompanied by the production of ECM 
molecules and matrix vesicles is promoted under the metabolic support by CCN2.  The 
schema also indicates that CCN2 may enhance the activity and migration of osteoblasts 
and vascular endothelial cells.  
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